NTRR to commence Pure Plus clinical trial
The trial follows the shipment of initial test batch as well as Pure Plus from the manufacturer to a laboratory for a highly specialised Bio-energy infusion that enhnaces

The trial follows the shipment of initial test batch as well as Pure Plus from the manufacturer to a laboratory for a highly specialised Bio-energy infusion that enhnaces

The neonatal product is based on an established and approved inotropic agent, and will be used in clinical trial researching and treating critically ill premature babies suffering from

The US Food and Drug Administration approved Eletone Cream is a non-steroidal, barrier cream for the long term treatment of atopic dermatitis, an inflammatory, chronically relapsing, non-contagious and

The new investment includes capital expenditures and labour costs, as well as preclinical studies for a rabies vaccine and other products. The company anticipates this investment to enhance

The FDA-approved NitroMist is a nitrate vasodilator indicated for acute relief of an attack or acute prophylaxis of angina pectoris (chest pain) due to coronary artery disease. Developed

IDX184 is a pan-genotypic oral nucleotide polymerase inhibitor, used for the treatment of hepatitis C virus (HCV) infection. In September 2010, FDA has issued a clinical hold as

Dalfampridine, also known as 4-aminopyridine, is the active chemical ingredient in Ampyra (dalfampridine) extended release tablets, 10 mg. In the study, researchers evaluated functional improvement using a battery

TH-302 is a hypoxia-targeted drug that is thought to be activated under tumor hypoxic conditions. As per the agreement, Merck will receive co-development rights, exclusive global commercialization rights

The laboratory is a cGMP compliant facility and meets all FDA requirements to manufacture food supplements and over the counter pharmaceuticals, the company said. Azul Instant will be

JANUMET XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both sitagliptin and extended-release